121 related articles for article (PubMed ID: 32694422)
1. Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
Lin X; Zhang J; Wang X; Lin G; Chen T
Anticancer Drugs; 2020 Nov; 31(10):989-996. PubMed ID: 32694422
[TBL] [Abstract][Full Text] [Related]
2. Self-assembling peptide for co-delivery of HIV-1 CD8+ T cells epitope and Toll-like receptor 7/8 agonists R848 to induce maturation of monocyte derived dendritic cell and augment polyfunctional cytotoxic T lymphocyte (CTL) response.
Ding Y; Liu J; Lu S; Igweze J; Xu W; Kuang D; Zealey C; Liu D; Gregor A; Bozorgzad A; Zhang L; Yue E; Mujib S; Ostrowski M; Chen P
J Control Release; 2016 Aug; 236():22-30. PubMed ID: 27297778
[TBL] [Abstract][Full Text] [Related]
3. Conjugation of toll-like receptor-7 agonist to gastric cancer antigen MG7-Ag exerts antitumor effects.
Wang XD; Gao NN; Diao YW; Liu Y; Gao D; Li W; Wan YY; Zhong JJ; Jin GY
World J Gastroenterol; 2015 Jul; 21(26):8052-60. PubMed ID: 26185376
[TBL] [Abstract][Full Text] [Related]
4. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
5. R848/TLR7-Mediated Stronger CD8+ T Immunity Is Dependent on DC-NK Cell Interactions.
Zhou J; Nouri-Shirazi M; Tang H; Shen Y; Zeng M
Int Arch Allergy Immunol; 2022; 183(8):860-875. PubMed ID: 35263757
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
Rostamian M; Niknam HM
Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
[TBL] [Abstract][Full Text] [Related]
7. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
8. Systemic delivery of a TLR7 agonist in combination with radiation primes durable antitumor immune responses in mouse models of lymphoma.
Dovedi SJ; Melis MH; Wilkinson RW; Adlard AL; Stratford IJ; Honeychurch J; Illidge TM
Blood; 2013 Jan; 121(2):251-9. PubMed ID: 23086756
[TBL] [Abstract][Full Text] [Related]
9. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
Schölch S; Rauber C; Tietz A; Rahbari NN; Bork U; Schmidt T; Kahlert C; Haberkorn U; Tomai MA; Lipson KE; Carretero R; Weitz J; Koch M; Huber PE
Oncotarget; 2015 Mar; 6(7):4663-76. PubMed ID: 25609199
[TBL] [Abstract][Full Text] [Related]
10. Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.
Ye J; Mills BN; Qin SS; Garrett-Larsen J; Murphy JD; Uccello TP; Han BJ; Vrooman TG; Johnston CJ; Lord EM; Belt BA; Linehan DC; Gerber SA
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35851308
[TBL] [Abstract][Full Text] [Related]
11. Toll-like receptor 4, Toll-like receptor 7 and Toll-like receptor 9 agonists enhance immune responses against blood-stage Plasmodium chabaudi infection in BALB/c mice.
Gao W; Sun X; Li D; Sun L; He Y; Wei H; Jin F; Cao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107096. PubMed ID: 33091818
[TBL] [Abstract][Full Text] [Related]
12. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
[TBL] [Abstract][Full Text] [Related]
13. Suppressive effect of β,β-dimethylacryloyl alkannin on activated dendritic cells in psoriasis by the TLR7/8 pathway.
Wang Y; Zhao J; Di T; Wang M; Ruan Z; Zhang L; Xie X; Meng Y; Lin Y; Liu X; Wang N; Li P
Int Immunopharmacol; 2016 Nov; 40():410-418. PubMed ID: 27697724
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.
Ito H; Ando T; Arioka Y; Saito K; Seishima M
Immunology; 2015 Apr; 144(4):621-30. PubMed ID: 25322876
[TBL] [Abstract][Full Text] [Related]
15. The TLR7 ligand R848 prevents mouse graft-
Gaignage M; Marillier RG; Cochez PM; Dumoutier L; Uyttenhove C; Coutelier JP; Van Snick J
Haematologica; 2019 Feb; 104(2):392-402. PubMed ID: 30213828
[TBL] [Abstract][Full Text] [Related]
16. Dual activation of Toll-like receptors 7 and 9 impairs the efficacy of antitumor vaccines in murine models of metastatic breast cancer.
Moreno Ayala MA; Gottardo MF; Gori MS; Nicola Candia AJ; Caruso C; De Laurentiis A; Imsen M; Klein S; Bal de Kier Joffé E; Salamone G; Castro MG; Seilicovich A; Candolfi M
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1713-1732. PubMed ID: 28432455
[TBL] [Abstract][Full Text] [Related]
17. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
18. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
19. Persistent Toll-like receptor 7 stimulation induces behavioral and molecular innate immune tolerance.
Michaelis KA; Norgard MA; Levasseur PR; Olson B; Burfeind KG; Buenafe AC; Zhu X; Jeng S; McWeeney SK; Marks DL
Brain Behav Immun; 2019 Nov; 82():338-353. PubMed ID: 31499172
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.
Mullins SR; Vasilakos JP; Deschler K; Grigsby I; Gillis P; John J; Elder MJ; Swales J; Timosenko E; Cooper Z; Dovedi SJ; Leishman AJ; Luheshi N; Elvecrog J; Tilahun A; Goodwin R; Herbst R; Tomai MA; Wilkinson RW
J Immunother Cancer; 2019 Sep; 7(1):244. PubMed ID: 31511088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
